Daejeon, South Korea

Jinil Choi

USPTO Granted Patents = 1 

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jinil Choi: Innovator in Pharmaceutical Compounds

Introduction

Jinil Choi, an accomplished inventor based in Daejeon, South Korea, has made significant contributions to the field of pharmaceutical innovations. His research primarily focuses on developing compounds that can aid in treating central nervous system disorders.

Latest Patents

Jinil Choi holds one notable patent, titled "3-aryl-3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same." This invention relates to compounds acting as 5HT6 receptor antagonists, which are valuable for addressing disorders related to the 5HT6 receptor. The compounds he developed possess an excellent binding affinity and selectivity specifically for the 5HT6 receptor, distinguishing them from other receptors and enhancing their therapeutic potential.

Career Highlights

Currently, Jinil is associated with the Korea Research Institute of Chemical Technology, where he works on pioneering pharmaceutical innovations. His dedication to research and development plays a crucial role in advancing medications that address complex health issues.

Collaborations

Throughout his career, Jinil Choi has collaborated with esteemed colleagues, including Churlmin Seong and Nosang Park. These partnerships have fostered an environment of innovation, enabling the exploration of new ideas and the development of effective pharmaceutical solutions.

Conclusion

Jinil Choi exemplifies the spirit of innovation within the pharmaceutical industry. His work on 3-aryl-3-methyl-quinoline-2,4-diones and their potential applications in treating central nervous system disorders showcases his commitment to advancing medical science. As he continues to collaborate and innovate, his contributions may significantly impact future therapeutic developments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…